Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - The Australian Red Cross Blood Service: Blood Donor Centre Adelaide

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and other dealings with therapeutic goods in Australia, including medicines, medical devices, and blood products. The Act was introduced to address the need for a comprehensive regulatory framework to ensure the safety, efficacy, and quality of therapeutic goods available to the public. The Therapeutic Goods Administration (TGA), established under the Act, is responsible for administering and enforcing the provisions of the Act. The policy objective behind the Act is to protect public health by ensuring that therapeutic goods meet acceptable standards of quality, safety, and efficacy. In a recent development, the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, had its licence to manufacture therapeutic goods revoked at its request. The licence, MI-25082005-LI-000865-1, pertains to the Blood Donor Centre in Adelaide and was formally revoked by the Secretary under paragraph 41(1)(d) of the Act. This action was published in the Gazette by Bill Turner, who is the delegate of the Secretary for the purpose of section 41 of the Therapeutic Goods Act 1989.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, supply, importation, or advertising of therapeutic goods in Australia. This includes pharmaceutical products, medical devices, and biologicals. The Act applies across the Commonwealth and regulates activities within all states and territories, ensuring a uniform standard for therapeutic goods nationwide. The revocation of a manufacturer’s licence, as described in this particular notice, falls under the purview of section 41 of the Act, which empowers the Secretary to revoke a licence upon the manufacturer's request or for other valid reasons. The revocation applies specifically to the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, for their blood donor centre in Adelaide. This revocation does not extend to other divisions or entities within the Australian Red Cross unless specifically addressed by further notices or provisions under the Act. The Act may also allow for exclusions or exemptions in certain cases, which would be detailed in subordinate instruments or specific legislative provisions.

Key Provisions

The Therapeutic Goods Act 1989 (section 41) outlines the process by which the Secretary can revoke a licence for the manufacture of therapeutic goods. In this case, under paragraph 41(1)(d), the Secretary has revoked the licence of the Australian Red Cross Blood Service, an operating division of the Australian Red Cross Society, located at the Blood Donor Centre in Adelaide, with the licence number MI-25082005-LI-000865-1. The revocation was made at the request of the manufacturer, and it is effective from the date of the notice, 18 December 2012. This action directly impacts the entity's ability to continue manufacturing therapeutic goods, effectively ending their licensed operations. The obligations imposed by the Therapeutic Goods Act 1989 on entities such as the Australian Red Cross Blood Service include maintaining a valid licence to manufacture therapeutic goods. This licence ensures that the entity adheres to the stringent quality, safety, and efficacy standards required for the production of these goods. When a licence is revoked, the entity must cease all activities related to the manufacture of therapeutic goods as per the terms of the Act. Failure to comply with these obligations can lead to serious consequences, including potential legal action. Breaching the conditions of the Therapeutic Goods Act 1989 can result in both civil and criminal penalties. For example, continuing to manufacture therapeutic goods without a valid licence can be considered an offence under the Act. The maximum penalties for such breaches are not explicitly stated in the notice but can include substantial fines and imprisonment depending on the severity of the offence. Additionally, the entity may face further administrative actions, such as being placed on a public list of revoked manufacturers, which can severely impact their reputation and future operations in the sector. It is crucial for entities within the scope of the Therapeutic Goods Act 1989 to understand and comply with their obligations to avoid the severe consequences associated with non-compliance. The revocation of a licence not only affects the entity’s operational status but also has broader implications for public health and safety. Consequently, entities must ensure they maintain all necessary licences and adhere to regulatory standards to prevent such outcomes.